Ainos (NASDAQ:AIMD) Shares Down 1.5% – Here’s Why

Shares of Ainos, Inc. (NASDAQ:AIMD) fell 1.5% on Tuesday . The stock traded as low as $1.30 and last traded at $1.31. Approximately 17,485 shares were traded during trading, a decline of 68% from the average daily volume of 55,193 shares. The stock had previously closed at $1.33.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, May 26th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Ainos presently has a consensus rating of “Sell”.

Ainos Stock Down 1.5%

The company has a debt-to-equity ratio of 1.58, a quick ratio of 0.50 and a current ratio of 0.55. The stock has a market capitalization of $11.16 million, a price-to-earnings ratio of -0.45 and a beta of 2.43. The firm’s fifty day simple moving average is $1.90 and its 200 day simple moving average is $1.75.

Ainos (NASDAQ:AIMD) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.41) earnings per share for the quarter. Ainos had a negative net margin of 11,912.10% and a negative return on equity of 160.55%.

Insider Activity at Ainos

In other Ainos news, Director Ting-Chuan Lee sold 109,988 shares of the stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $1.90, for a total transaction of $208,977.20. Following the completion of the transaction, the director owned 807,417 shares in the company, valued at approximately $1,534,092.30. This represents a 11.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Chun-Jung Tsai sold 27,718 shares of the stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $1.87, for a total value of $51,832.66. Following the transaction, the director owned 658,199 shares of the company’s stock, valued at approximately $1,230,832.13. This trade represents a 4.04% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have purchased 7,800 shares of company stock valued at $15,946 and have sold 179,788 shares valued at $359,247. 9.79% of the stock is currently owned by insiders.

Institutional Trading of Ainos

A number of institutional investors have recently modified their holdings of AIMD. DRW Securities LLC boosted its position in shares of Ainos by 272.6% during the fourth quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock worth $109,000 after buying an additional 48,439 shares during the period. Two Sigma Investments LP acquired a new stake in Ainos in the 3rd quarter valued at approximately $80,000. Mariner LLC acquired a new stake in Ainos in the 4th quarter valued at approximately $37,000. Finally, Renaissance Technologies LLC lifted its stake in Ainos by 13.1% in the 4th quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock valued at $109,000 after acquiring an additional 7,700 shares in the last quarter.

About Ainos

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.